Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience
Open Access
- 17 September 2019
- journal article
- review article
- Published by Wiley in Aging Medicine
- Vol. 2 (3) , 142-146
Abstract
Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—“healthy aging”—has paradoxically lagged to parallel this increase. Consequently, aging‐associated illnesses, such as Alzheimer's disease and aging frailty, are having a growing impact on patients, their families, and entire health‐care systems. Typically, such disorders have been treated as isolated disease entities. However, the inextricable links between aging‐associated disorders and the aging process itself have become increasingly recognized, leading to formation of the field of geroscience. The geroscience concept is that treating the aging process itself should lead to treatment and prevention of aging‐related disorders. However, the aging process is complex, dictated by highly interrelated pleiotropic processes. As such, therapeutics with pleiotropic mechanisms of action (either alone, or as part of combinatorial strategies) will be required for preventing and treating both aging and related disorders. Mesenchymal stem cells (MSCs) have multiple mechanisms of action that make these highly promising geroscience therapeutic candidates. These cells have a high safety profile for clinical use, are amenable to allogeneic use since tissue‐type matching is not required, and can have sustained activity after transplantation. Herein, we review preclinical and clinical data supporting the utility of allogeneic MSCs as a geroscience therapeutic candidate.Keywords
Funding Information
- Office of Extramural Research (1R42AG054322‐01A1, 1R44AG062015‐01, 4R44AG062015‐02, 4R42AG054322‐02)
- Alzheimer's Association (PTC C‐16‐422443, PTC‐CS‐19‐623225)
This publication has 56 references indexed in Scilit:
- Homocysteine and Dementia: An International Consensus StatementJournal of Alzheimer’s Disease, 2018
- Geroscience and the trans-NIH Geroscience Interest Group, GSIGGeroScience, 2017
- The independent role of inflammation in physical frailty among older adults with mild cognitive impairment and mild-to-moderate Alzheimer's diseaseThe Journal of nutrition, health and aging, 2016
- Geroscience: Linking Aging to Chronic DiseaseCell, 2014
- The Hallmarks of AgingCell, 2013
- Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ StudyMechanisms of Ageing and Development, 2012
- Inflammation and frailty measures in older peopleJournal of Cellular and Molecular Medicine, 2009
- Higher Inflammatory Marker Levels in Older Persons: Associations With 5-Year Change in Muscle Mass and Muscle StrengthThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2009
- Frailty Syndrome is Associated with Altered Circulating Redox Balance and Increased Markers of Oxidative StressInternational Journal of Immunopathology and Pharmacology, 2009
- Relationship of Interleukin-6 and Tumor Necrosis Factor- With Muscle Mass and Muscle Strength in Elderly Men and Women: The Health ABC StudyThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2002